| pubmed-article:18614347 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:18614347 | lifeskim:mentions | umls-concept:C0024117 | lld:lifeskim |
| pubmed-article:18614347 | lifeskim:mentions | umls-concept:C1280500 | lld:lifeskim |
| pubmed-article:18614347 | lifeskim:mentions | umls-concept:C0073992 | lld:lifeskim |
| pubmed-article:18614347 | lifeskim:mentions | umls-concept:C0117996 | lld:lifeskim |
| pubmed-article:18614347 | pubmed:issue | 8 | lld:pubmed |
| pubmed-article:18614347 | pubmed:dateCreated | 2008-7-22 | lld:pubmed |
| pubmed-article:18614347 | pubmed:abstractText | COPD exacerbations are associated with significant morbidity and mortality. This randomized, double-blind, parallel-group, multicenter study evaluated the effect of fluticasone propionate/salmeterol 250/50 and salmeterol 50 microg twice daily on moderate to severe exacerbations. | lld:pubmed |
| pubmed-article:18614347 | pubmed:language | eng | lld:pubmed |
| pubmed-article:18614347 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18614347 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:18614347 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18614347 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18614347 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18614347 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18614347 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18614347 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18614347 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:18614347 | pubmed:month | Aug | lld:pubmed |
| pubmed-article:18614347 | pubmed:issn | 0954-6111 | lld:pubmed |
| pubmed-article:18614347 | pubmed:author | pubmed-author:AnzuetoAntoni... | lld:pubmed |
| pubmed-article:18614347 | pubmed:author | pubmed-author:EmmettAmandaA | lld:pubmed |
| pubmed-article:18614347 | pubmed:author | pubmed-author:KnobilKathari... | lld:pubmed |
| pubmed-article:18614347 | pubmed:author | pubmed-author:FergusonGary... | lld:pubmed |
| pubmed-article:18614347 | pubmed:author | pubmed-author:KalbergChrist... | lld:pubmed |
| pubmed-article:18614347 | pubmed:author | pubmed-author:FeiRichardR | lld:pubmed |
| pubmed-article:18614347 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:18614347 | pubmed:volume | 102 | lld:pubmed |
| pubmed-article:18614347 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:18614347 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:18614347 | pubmed:pagination | 1099-108 | lld:pubmed |
| pubmed-article:18614347 | pubmed:meshHeading | pubmed-meshheading:18614347... | lld:pubmed |
| pubmed-article:18614347 | pubmed:meshHeading | pubmed-meshheading:18614347... | lld:pubmed |
| pubmed-article:18614347 | pubmed:meshHeading | pubmed-meshheading:18614347... | lld:pubmed |
| pubmed-article:18614347 | pubmed:meshHeading | pubmed-meshheading:18614347... | lld:pubmed |
| pubmed-article:18614347 | pubmed:meshHeading | pubmed-meshheading:18614347... | lld:pubmed |
| pubmed-article:18614347 | pubmed:meshHeading | pubmed-meshheading:18614347... | lld:pubmed |
| pubmed-article:18614347 | pubmed:meshHeading | pubmed-meshheading:18614347... | lld:pubmed |
| pubmed-article:18614347 | pubmed:meshHeading | pubmed-meshheading:18614347... | lld:pubmed |
| pubmed-article:18614347 | pubmed:meshHeading | pubmed-meshheading:18614347... | lld:pubmed |
| pubmed-article:18614347 | pubmed:meshHeading | pubmed-meshheading:18614347... | lld:pubmed |
| pubmed-article:18614347 | pubmed:meshHeading | pubmed-meshheading:18614347... | lld:pubmed |
| pubmed-article:18614347 | pubmed:meshHeading | pubmed-meshheading:18614347... | lld:pubmed |
| pubmed-article:18614347 | pubmed:meshHeading | pubmed-meshheading:18614347... | lld:pubmed |
| pubmed-article:18614347 | pubmed:meshHeading | pubmed-meshheading:18614347... | lld:pubmed |
| pubmed-article:18614347 | pubmed:meshHeading | pubmed-meshheading:18614347... | lld:pubmed |
| pubmed-article:18614347 | pubmed:year | 2008 | lld:pubmed |
| pubmed-article:18614347 | pubmed:articleTitle | Effect of fluticasone propionate/salmeterol (250/50 microg) or salmeterol (50 microg) on COPD exacerbations. | lld:pubmed |
| pubmed-article:18614347 | pubmed:affiliation | Pulmonary Research Institute of Southeast Michigan, 28807 Eight Mile Road, Suite 103, Livonia, MI 48152, USA. garytferguson@msn.com | lld:pubmed |
| pubmed-article:18614347 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:18614347 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| pubmed-article:18614347 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:18614347 | pubmed:publicationType | Multicenter Study | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18614347 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18614347 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18614347 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18614347 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18614347 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18614347 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18614347 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18614347 | lld:pubmed |
